Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: A review

EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016

(2017) Marko Babjuk et al.   EUROPEAN UROLOGY

Immunotherapy for the Treatment of Urothelial Carcinoma

(2017) Nicholas M. Donin et al.   JOURNAL OF UROLOGY

BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG

(2017) Ashish M. Kamat et al.   Nature Reviews Urology

Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline

(2016) Sam S. Chang et al.   JOURNAL OF UROLOGY

Intravesical and alternative bladder-preservation therapies in the management of non–muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin

(2016) Ryan L. Steinberg et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer

(2015) Patrick A. Cockerill et al.   BJU INTERNATIONAL

CUA guidelines on the management of non-muscle invasive bladder cancer

(2015) Wassim Kassouf et al.   CUAJ-Canadian Urological Association Journal

Low-Dose Versus Standard Dose of Bacillus Calmette-Guerin in the Treatment of Nonmuscle Invasive Bladder Cancer

(2015) Shuxiong Zeng et al.   MEDICINE

Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

(2015) Ashish M. Kamat et al.   Nature Reviews Urology

Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials?

(2015) Vincenzo Serretta et al.   UROLOGIA INTERNATIONALIS

Bacillus Calmette-Guérin Strain Differences Have an Impact on Clinical Outcome in Bladder Cancer Immunotherapy

(2014) Cyrill A. Rentsch et al.   EUROPEAN UROLOGY

The Effect of Age on the Efficacy of Maintenance Bacillus Calmette-Guérin Relative to Maintenance Epirubicin in Patients with Stage Ta T1 Urothelial Bladder Cancer: Results from EORTC Genito-Urinary Group Study 30911

(2014) Jorg R. Oddens et al.   EUROPEAN UROLOGY

The mechanism of action of BCG therapy for bladder cancer—a current perspective

(2014) Gil Redelman-Sidi et al.   Nature Reviews Urology

Optimal schedule of bacillus calmette-guerin for non-muscle-invasive bladder cancer: a meta-analysis of comparative studies

(2013) Shimiao Zhu et al.   BMC CANCER

SWOG S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Nonmuscle Invasive Bladder Cancer and Recurrence after 2 Prior Courses of Intravesical Bacillus Calmette-Guérin

(2013) Eila C. Skinner et al.   JOURNAL OF UROLOGY

Efficacy and Safety of Photodynamic Therapy for Recurrent, High Grade Nonmuscle Invasive Bladder Cancer Refractory or Intolerant to Bacille Calmette-Guérin Immunotherapy

(2013) Joo Yong Lee et al.   JOURNAL OF UROLOGY

Toll-like receptors in urothelial cells—targets for cancer immunotherapy

(2013) Hélène LaRue et al.   Nature Reviews Urology

Determining the Role of Cystectomy for High-grade T1 Urothelial Carcinoma

(2013) Siamak Daneshmand   UROLOGIC CLINICS OF NORTH AMERICA

Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non–muscle invasive bladder cancer

(2013) Andrew J. Lightfoot et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis

(2012) Baerin B. Houghton et al.   BJU INTERNATIONAL

Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

(2012) Jorg Oddens et al.   EUROPEAN UROLOGY

Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer

(2010) Giuseppe Di Lorenzo et al.   CANCER

A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy

(2009) LaMont Barlow et al.   BJU INTERNATIONAL

An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guérin for Non–Muscle-Invasive Bladder Cancer

(2009) Per-Uno Malmström et al.   EUROPEAN UROLOGY

Combined Thermo-Chemotherapy for Recurrent Bladder Cancer After Bacillus Calmette-Guerin

(2009) Ofer Nativ et al.   JOURNAL OF UROLOGY

Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder

(2008) Atsushi Takenaka et al.   INTERNATIONAL JOURNAL OF UROLOGY

Early Versus Deferred Cystectomy for Initial High-Risk pT1G3 Urothelial Carcinoma of the Bladder: Do Risk Factors Define Feasibility of Bladder-Sparing Approach?

(2007) Stefan Denzinger et al.   EUROPEAN UROLOGY

Prognostic Factors in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials

(2007) Jesus Fernandez-Gomez et al.   EUROPEAN UROLOGY

History of Bacillus Calmette-Guerin and Bladder Cancer: An Immunotherapy Success Story

(2007) Harry W. Herr et al.   JOURNAL OF UROLOGY